Pharma BD Deal Intelligence

Amgen Inc. / Immunex Corporation

2001 · Acquisition/Merger · $16.0B · Complete

Announcement Sentiment

Positive

Outcome Score

Worked — the deal delivered on its rationale.

Amgen acquired Immunex for approximately $16 billion in stock and cash, gaining full rights to Enbrel (etanercept), the blockbuster anti-TNF therapy for rheumatoid arthritis. The deal was 85% stock (0.44 Amgen shares per Immunex share) and 15% cash ($4.50 per share).

Key facts

Announced Dec 17, 2001
Closed Jul 16, 2002
Deal value $16.0B
Deal type Acquisition/Merger
Therapeutic area Dermatology, Immunology
Indications Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis
Key assets Enbrel (etanercept), Leukine (sargramostim)
Mechanism TNF receptor fusion protein (anti-TNF)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals